Steroid Diabetes in Patients With Kidney Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-01-10

Study Completion Date

2027-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

If steroid diabetes is not recognized in time, it will cause irreversible damage to the body. Nephropathy patients are more likely to have steroid diabetes ,the incidence rate up to 25%,due to hypoalbuminemia, high-dose hormone and other reasons, so they need to be closely followed up, identified and intervened in time.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Adiponectin and Insulin Resistance in Diabetic Nephropathy

NCT00774904

Diabetic Nephropathy

COMPLETED NA

Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 Diabetes

NCT06532682

Diabetic Kidney Disease Type 1 Diabetes

ACTIVE_NOT_RECRUITING PHASE4

Effect of Novel Antidiabetic Drug Combined With Angiotensin Receptor/Neprilysin Inhibitor on Urinary Protein

NCT05922852

Type 2 Diabetes Antidiabetic Drugs

UNKNOWN

Effect of Sulodexide on Albuminuria in Chinese Type 2 Diabetic Patients

NCT01316068

Diabetic Nephropathy Albuminuria

UNKNOWN PHASE4

Effects of Disease Management on Development of End Stage Renal Disease in Type 2 Diabetic Patients With Nephropathy

NCT00309127

Type 2 Diabetes Mellitus DM Nephropathy

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. Patients with nephrosis who had taken glucocorticoid for the first time were followed up, and those who had diabetes themselves were excluded.
2. Regularly follow up and record information on glucocorticoid medication, medications that have an impact on blood sugar, fasting blood sugar, 2-hour postprandial blood sugar, and glycated hemoglobin.
3. Notify relevant doctors of any cases of elevated blood sugar.
4. The total follow-up time is 1 year.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nephrotic Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Blood glucose management in patients with kidney disease after using glucocorticoids

Blood glucose monitoring for kidney disease patients after taking glucocorticoids

no intervention

Intervention Type OTHER

no intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

no intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients who need to use glucocorticoids due to the following diseases: nephrotic syndrome, Immunoglobulin A nephropathy, membranous nephropathy, Anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV), systemic lupus erythematosus；
2. Initial daily dose of glucocorticoids greater than or equal to 10mg of prednisolone；

Exclusion Criteria

1. Patients with diabetes；
2. Those who are unable to communicate through language；
3. Uremic patients；
4. Unable to perform blood glucose monitoring and follow-up as required；
5. Those who have used glucocorticoids within the past 3 months and have accumulated a dose of 10mg or more of prednisone；
6. Participated in other clinical studies。

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No